Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
fda
3
×
life sciences
national blog main
national top stories
new york blog main
3
×
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
advaxis
aimmune therapeutics
alder biopharmaceutical
alder biopharmaceuticals
alexander hardy
allergan
american academy of neurology
amgen
andrew oxtoby
atogepant
babies
biohaven
What
big
3
×
medicine
acquire
agreed
approval
arguments
billion
bio
bosley's
bosley’s
bridge
broad
bucks
cas
ceo
class
commercialized
companies
competitors
confidence
crime
crispr
decades
departure
didn’t
drug
drugs
editas
exit
fda
foundation
gain
genentech
guiding
katrine
make
meeting
migraine
momentum
morning
Language
Current search:
big
×
fda
×
biotech
×
" new york blog main "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine